ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies

(MedPage Today) -- The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news